AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06122129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscope with ureteral access sheath
Description: The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
Study NCT06122129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscope without ureteral access sheath
Description: Ureteroscopy will be carried out without a ureteral access sheath
Study NCT04906044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab combined withTotal Neoadjuvant Treatment
Study NCT05741567 — intervention group
Intervention type: PROCEDURE
Intervention: correction of anterior prolapse
Description: percentage of failed prolapse correction
Study NCT05502393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS107
Description: JS107, i.v., q3w
Study NCT05502393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab i.v., q3w
Study NCT05111158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mfERG
Description: mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
Study NCT06147310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Group
Description: The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
Study NCT06147310 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
Study NCT05451173 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
Study NCT05451173 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
Study NCT05451173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
Study NCT05553977 — intervention group
Intervention type: DRUG
Intervention: Bowel preparation for colonoscopy
Description: one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
Study NCT05553977 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy will be performed to every patient included in the study
Study NCT06217523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics-directed Hyperlipidaemia Management
Description: Pharmacogenomics-directed Hyperlipidaemia Management
Study NCT05743179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
Study NCT05620563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally
Study NCT05620563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05513079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy Based Counseling
Description: The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
Study NCT06495164 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: CDK4/6 inhibitor
Study NCT06495164 — intervention group
Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor
Study NCT05629975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements
Description: Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days.
Study NCT05555823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002
Description: 300 mg tablets for oral intake
Study NCT05555823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablets for oral intake
Study NCT05555823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repaglinide
Description: 0,5 mg tablets for oral intake
Study NCT05555823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: 100 mg capsules for oral intake
Study NCT06495164 — intervention group
Intervention type: DRUG
Intervention: Ribociclib
Description: CDK4/6 inhibitor
Study NCT06495164 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: CDK4/6 inhibitor
Study NCT05738044 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06525103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electromagnitic field therapy
Description: EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V
Study NCT06525103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels.
Study NCT06413043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
Study NCT05798910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALS VR (VR based serious gaming module for advanced life support training)
Description: Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
Study NCT05798910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture based training for advanced life support
Description: Taking part in a classical lecture about advanced life support.
Study NCT05870579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose.
Study NCT05870579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: Study participants will receive \[177Lu\]Lu-NeoB once every cycle
Study NCT05870579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg once daily (OD) days 1 to 21 every 28 days
Study NCT05870579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
Study NCT05870579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre/peri-menopausal women and men only.
Study NCT06162195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The H1 Implant
Description: Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
Study NCT06162195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless total hip replacement
Description: Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: ATC code: N06AB10
Study NCT04874350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1148
Description: LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
Study NCT04874350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo capsule
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: See arm description
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsules for oral administration.
Study NCT05405582 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Community-based differentiated HIV prevention incl.PrEP with SRH
Description: Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
Study NCT05405582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Health Clinic based HIV prevention and care
Description: Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Capsules for oral administration.
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate acid
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate acid
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: See arm description
Study NCT05973786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: See arm description
Study NCT04533542 — intervention group
Intervention type: OTHER
Intervention: Measurement
Description: Undergo sensory measurements
Study NCT04533542 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Capsules for oral administration.
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548 Placebo
Description: Tablets for oral administration.
Study NCT05818852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-548 Placebo
Description: Tablets for oral administration.
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive supplement
Description: Chewable candy (negative control), chewed for 30 seconds.
Study NCT06515470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-9341
Description: Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
Study NCT06515470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injections on Day 15 and then every 28 days
Study NCT06515470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-9341
Description: Daily oral dose in 28-day cycles using dose determined in Part A
Study NCT05870917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
Study NCT05280106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-dilution online hemodiafiltration with citrate dialysate
Description: After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate supplement
Description: Chewable tricalcium phosphate supplement, chewed for 30 seconds.
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplement
Description: Chewable calcium carbonate supplement, chewed for 30 seconds.
Study NCT05280106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration with citrate dialysate
Description: same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
Study NCT04723550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospital telemedicine management system
Description: Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
Study NCT04723550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium citrate supplement
Description: Chewable calcium citrate supplement, chewed for 30 seconds.
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive supplement and fluoride mouthwash
Description: A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplement and fluoride mouthwash
Description: A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study NCT04620252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium citrate supplement and fluoride mouthwash
Description: A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study NCT04546451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music practice
Description: Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
Study NCT04546451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor therapy
Description: Patients will be trained in body awareness and a wide range of of movement activities.
Study NCT06050941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Idarubicin 6mg/m2 d5-7
Study NCT06050941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 60mg/m2 d5-9
Study NCT04696016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin conductance guided antinociception
Description: The value of skin conductance guides the titration of sufentanil
Study NCT04696016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care antinociception
Description: The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
Study NCT06216899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-food based smoothie
Description: The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
Study NCT06216899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula
Description: Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
Study NCT05791994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual cognitive stimulation exercises
Description: Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
Study NCT05791994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Broadcast of a television program
Description: Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
Study NCT06492174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGENT DCB 40 mm
Description: Drug coated PTCA balloon catheter 40 mm size
Study NCT06443684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRD
Description: MRD（LC-10）include 10 lung cancer-related driver gene mutation site
Study NCT06489704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Echocardiography will be performed according to clinical standards
Study NCT04798274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
Study NCT04798274 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Theta Burst Stimulation
Description: Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
Study NCT05840055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis.